CClinicalTrials.gg
Status unknownNCT03365505Updated Dec 7, 2017

Frailty Assessment in Elderly Patients With Acute Coronary Syndrome

An observational study in Frail Elderly Syndrome and Acute Coronary Syndrome, sponsored by Meir Medical Center. Status unknown. Open to participants aged 80 Years to 120 Years. Per ClinicalTrials.gov, last updated 2017-12-07.

Sponsored by Meir Medical Center · Observational

The sponsor has not verified this record recently (last verified Dec 2017), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
80 Years to 120 Years
Sex
All
01

Study summary

Frailty is known as an independent risk factor for morbidity and mortality in older cardiac patients . It is an important factor on the cardiologist decision between conservative and invasive treatment in older patient with acute coronary syndrome, and is usually made subjectively by the cardiologist known in the literature as eyeball testing.

in this study the investigators will compare the cardiologists eye ball testing to objective frailty assessment based on Fried score and Edmonton frailty scale.

Read the detailed description

elderly patients admitted to Meir hospital with acute coronary syndrome will be assessed for frailty twice: the first frailty assessment will be a subjective eye ball testing made by the cardiologist, the second assessment will be an objective one based on Fried frailty score and Edmonton frail scale.

The cardiologist will not be aware of the objective frailty assessment result.

The eye ball testing will be compared to the objective frailty assessment (Fried score and Edmonton frailty scale).

02

Conditions studied

  • Frail Elderly Syndrome
  • Acute Coronary Syndrome
03

Who can participate

Ages eligible
80 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

elderly patient admitted to our hospital with acute coronary syndrome: unstable angina or non ST elevation myocardial infarction who are aged 80 and above and are hemodinamically stable.

Inclusion criteria

  • patient admitted to Meir hospital with acute coronary syndrome
  • Age: 80 years old and older
  • eligible for signing an informed concent

Exclusion criteria

Exclusion Criteria:

  • uncontrolled heart failure ( pulmonary edema or the use of iv diuretics)
  • cardiogenic shock
  • fever st elevation myocardial infarction
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
05

What researchers measure

Primary outcomes

  1. A subjective eye ball frailty assessment will be compared to an objective frailty assessment based on Fried score and Edmonton frailty scale

    Subjective frailty assessment made by a cardiologist during hospitalization with acute coronary syndrome- "eye ball" testing

    Time frame: Through hospitalization , an average of 1 week

  2. An objective frailty assessment using Fried score and Edmonton frailty scale will be compared to a subjective eye ball frailty assessment

    An objective frailty assessment based on Fried score and Edmonton frailty scale

    Time frame: Through hospitalization , an average of 1 week

06

Study locations

No study locations are listed for this record.

07

Registry details

Key details

Study ID
NCT03365505
Lead sponsor
Meir Medical Center
Responsible party
Sponsor
First posted
Dec 7, 2017
Start date
Dec 15, 2017 (estimated)
Primary completion
Sep 15, 2018 (estimated)
Completion
Sep 15, 2018 (estimated)
Last update
Dec 7, 2017

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion